ArticleJournal of managed care & specialty pharmacy2024

Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023.

Brady Wisniewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.